Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with pancreatic cancer. The company has scientific collaborations with pancreatic disease experts Cedars Sinai Medical Center in Los Angeles, the University of Miami; the University of Florida; the Austin Health Cancer Trials Centre in Melbourne, Australia; the Ashford Cancer Centre in Adelaide, Australia; and the Blacktown Cancer and Haematology Centre in Sydney, Australia. Sun BioPharma, Inc. was founded in 2011 and is based in Waconia, Minnesota.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone952-479-1196
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees4
Next Earnings DateN/A
OptionableNot Optionable
Sun BioPharma (NASDAQ:SNBP) Frequently Asked Questions
What is Sun BioPharma's stock symbol?
Sun BioPharma trades on the NASDAQ under the ticker symbol "SNBP."
Has Sun BioPharma been receiving favorable news coverage?
News coverage about SNBP stock has trended very negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sun BioPharma earned a media sentiment score of -3.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Sun BioPharma.
Who are some of Sun BioPharma's key competitors?
Some companies that are related to Sun BioPharma include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF), Cardiome Pharma (COM), China Longyi Group Int'l (CGYG), Creative Medical Technology (CELZ) and Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs (CYCCP).
What other stocks do shareholders of Sun BioPharma own?
Who are Sun BioPharma's key executives?
Sun BioPharma's management team includes the folowing people:
- Dr. Michael T. Cullen Jr., Co-Founder, Exec. Chairman, Pres & CEO (Age 73)
- Ms. Susan Horvath, VP of Fin., CFO, Sec. & Treasurer (Age 60)
- Dr. Thomas X. Neenan, Co-Founder & Chief Scientific Officer
- Ms. Tammy Groene, VP of Operations
- Dr. Suzanne Gagnon, Chief Medical Officer & Director (Age 62)
How do I buy shares of Sun BioPharma?
Shares of SNBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sun BioPharma's stock price today?
One share of SNBP stock can currently be purchased for approximately $4.50.
What is Sun BioPharma's official website?
How can I contact Sun BioPharma?
The company can be reached via phone at 952-479-1196.
MarketBeat Community Rating for Sun BioPharma (NASDAQ SNBP)
MarketBeat's community ratings are surveys of what our community members think about Sun BioPharma and other stocks. Vote "Outperform" if you believe SNBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
